Skip to textbook content
Doctor’s PassportTextbook
QuestionsFlashcardsBriefsDashboardAccount
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Renal and autoimmune disease

Obstetrics and gynaecology · UK scope · Sources checked 7 Sept 2026 · Clinical review pending

RapidFull
!
Rising creatinine with systemic deterioration

Oliguria, pulmonary oedema, severe hypertension, hyperkalaemia or rapidly evolving neurological symptoms in a pregnant patient with kidney or autoimmune disease require urgent hospital assessment. A known diagnosis of lupus does not explain every deterioration.

Action: Arrange immediate obstetric and renal review, with rheumatology and critical care when indicated. Assess circulation, oxygenation, fluid balance and urine output; obtain urgent renal, hepatic, haematological and urine studies while investigating pre-eclampsia, infection, thrombotic microangiopathy and inflammatory relapse in parallel.

Synopsis

Interpret renal changes during pregnancy, distinguish inflammatory relapse from placental disease, and maintain effective treatment while protecting maternal and fetal health.

  • Assess renal function in pregnancy using serum creatinine and its trajectory; laboratory eGFR equations are not validated for pregnancy.
  • Record early pregnancy blood pressure and quantified urine protein so that later changes have an interpretable baseline.
  • Aim for conception during sustained disease control on medicines suitable for pregnancy; active lupus nephritis particularly increases adverse outcomes.
  • Continue effective pregnancy-compatible treatment such as hydroxychloroquine; abrupt withdrawal may provoke a damaging autoimmune flare.
  • New hypertension or organ dysfunction after 20 weeks warrants assessment for superimposed pre-eclampsia, including in patients already proteinuric.
  • Anti-Ro/SSA and anti-La/SSB antibodies require counselling and a fetal and neonatal assessment plan, even if maternal symptoms are mild.
  • Nephrotic-range proteinuria warrants assessment for antenatal and postpartum thromboprophylaxis, alongside bleeding and delivery considerations.

Key red flags

New breathlessness or hypoxaemia accompanied by reduced urine output or rapidly increasing oedema.

Sustained systolic blood pressure of 160 mmHg or above or diastolic pressure of 110 mmHg or above, severe headache, visual disturbance or epigastric pain.

A creatinine concentration rising substantially from the patient's pregnancy baseline, even if the laboratory flags it as normal.

Fever or rigors during immunosuppression, especially with hypotension, confusion or flank pain.

Haemolysis, falling platelets and kidney injury that persist or worsen after birth.

Investigation priorities

01
Serum creatinine and electrolytesFirst step

Define renal reserve and detect evolving kidney injury.

Management branches

Before conceptionStabilise disease and revise medicines

A patient with CKD or systemic autoimmune disease is considering pregnancy.

  1. Review renal function, blood pressure, proteinuria, previous organ involvement and obstetric history in a joint specialist consultation.
  2. For lupus nephritis or vasculitis, aim for disease quiescence for at least six months before conception, explaining that individual risk also depends on residual organ damage.
  3. Replace teratogenic immunosuppression before attempting pregnancy and demonstrate stability on an effective alternative. Mycophenolate requires at least six weeks off treatment before conception; renal guidance advises a three-month interval to support conversion and stability.
  4. Agree how ACE inhibitors or angiotensin receptor blockers will be withdrawn or replaced, taking account of the renal indication and pregnancy detection plan. Arrange pregnancy-compatible blood pressure control and contraceptive cover during treatment changes.
  5. Discuss anti-Ro/La or antiphospholipid findings, inherited disease counselling where appropriate, aspirin eligibility and the anticipated antenatal team.

Key medicines

HydroxychloroquineContinue the established oral regimen, usually 200–400 mg daily; BSR pregnancy guidance supports doses up to 400 mg daily. Individualise the dose for disease control, body size, renal function and toxicity risk.Do not discontinue solely because pregnancy is confirmed. Check relevant ocular monitoring, interactions and renal impairment; breastfeeding is compatible under BSR guidance, with individual review of the complete regimen.
PrednisoloneUse the lowest oral dose that controls the specific inflammatory manifestation. BSR advises keeping the dose below 20 mg daily where possible and tapering with effective pregnancy-compatible steroid-sparing treatment; severe organ disease may require specialist higher-dose or intravenous treatment.Dose and duration depend on the affected organ and response. Monitor blood pressure, glucose, infection and adrenal suppression; avoid abrupt withdrawal after prolonged treatment and plan intrapartum steroid cover when indicated.
Open full textbook →Answer 2 questions
Sources and review status6 sources · checked 7 Sept 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.

  • UK Kidney Association pregnancy and renal disease guideline
  • Clinical practice guideline on pregnancy and renal disease full publication
  • BSR prescribing antirheumatic medicines in pregnancy and breastfeeding
  • BSR systemic lupus erythematosus guideline 2026
  • NICE NG121 intrapartum care with existing medical conditions
  • NICE NG133 hypertension in pregnancy recommendations

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom